Gilead Sciences has reported Q1 2026 total revenue of USD 7.0 billion, a 4% increase year-on-year, with product sales rising 5% to USD 6.9 billion. The HIV franchise remains the core growth driver, contributing USD 5.0 billion, a 10% increase, and representing 72% of total revenue.

Key performers included the flagship therapy Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide), which grew 7% to USD 3.4 billion, and the long-acting preventive therapy Yeztugo (lenacapavir), which generated USD 166 million, a 72% sequential increase following its 2025 US launch.

In oncology, sales of the company's CAR-T therapies declined 12% to a combined USD 407 million. This was offset by strong performance of the TROP2 ADC Trodelvy (sacituzumab govitecan), which grew 37% to USD 402 million. Based on the first-quarter performance, Gilead raised its full-year 2026 product sales guidance to a range of USD 30.0 billion to USD 30.4 billion.

PharmCube's NextBiopharm® database shows that Todelvy was the first TROP2 ADC to gain approval globally, enjoying market exclusivity for over 4 years until MSD and AstraZeneca's contenders entered the market. Click here to request a free trial for NextBiopharm®.